Treatment with biosimilar drug improves progression-free survival in breast cancer patients

Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.
News-Medical.Net Women’s Health News Feed

Submit comment

Allowed HTML tags: <a href="http://google.com">google</a> <strong>bold</strong> <em>emphasized</em> <code>code</code> <blockquote>
quote
</blockquote>